Treatment Of Idiopathic Pulmonary Fibrosis
Publication Date: July 1, 2015
Last Updated: September 2, 2022
Treatment
For patients with IPF, the guideline committee recommends:
Clinicians NOT use imatinib. ( Moderate , S, M)
695
Clinicians NOT use warfarin anticoagulation in patients who do not have a known alternative indication for its use. ( Low , S, L)
695
Clinicians NOT use the combination therapy of N-acetylcysteine, azathioprine, and prednisone. ( Low , S, L)
695
Clinicians NOT use ambrisentan, a selective ER-A endothelin receptor antagonist, regardless of the presence or absence of PH. ( Low , S, L)
695
Title
Treatment Of Idiopathic Pulmonary Fibrosis
Authoring Organization
American Thoracic Society